APA (7th ed.) Citation

Salah, S., Kobayashi, T., Ito, K., Kita, Y., Horani, M., Alshangiti, A., . . . Al-Rabi, K. (2024). 2008P Assessing response durability and survival after second-line pembrolizumab in advanced urothelial carcinoma: A multicenter validation of a risk model. Annals of Oncology, 35, S1159. https://doi.org/10.1016/j.annonc.2024.08.2094

Chicago Style (17th ed.) Citation

Salah, S., et al. "2008P Assessing Response Durability and Survival After Second-line Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Validation of a Risk Model." Annals of Oncology 35 (2024): S1159. https://doi.org/10.1016/j.annonc.2024.08.2094.

MLA (9th ed.) Citation

Salah, S., et al. "2008P Assessing Response Durability and Survival After Second-line Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Validation of a Risk Model." Annals of Oncology, vol. 35, 2024, p. S1159, https://doi.org/10.1016/j.annonc.2024.08.2094.